Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5144/0256-4947.1996.323 | DOI Listing |
Ear Nose Throat J
January 2025
Department of Hematology, Ataturk University School of Medicine, Erzurum, Turkey.
Int J Radiat Oncol Biol Phys
January 2025
Department of Radiation Oncology, University of Leipzig Medical Center, Leipzig, Germany; Comprehensive Cancer Center Central Germany, Partner Site Leipzig, Leipzig, Germany; Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, German Cancer Consortium (DKTK), Partner site DKTK, Freiburg, Germany. Electronic address:
Purpose: The value of stereotactic body radiotherapy (SBRT) in patients with oligometastatic head-and-neck squamous cell carcinoma (HNSCC) remains unclear, as existing evidence is primarily derived from retrospective single-center analyses with small patient cohorts. This study aimed to evaluate the outcomes of pulmonary SBRT in patients with oligometastatic HNSCC and to identify factors associated with survival.
Methods: This trinational multicenter cohort study, including 16 centers from XXX, XXX, and XXX, retrospectively analyzed patients with oligometastatic HNSCC undergoing SBRT for pulmonary metastases between 2010 and 2023.
Objective: This study aims to compare the effectiveness of 2 artificial saliva substitutes (Biotène vs HydraSmile) in the symptomatic management of radiation-induced xerostomia.
Study Design: Randomized double-blind cross-over study.
Setting: Single tertiary care academic institution.
Cancer Epidemiol
January 2025
Clinical Epidemiology Program, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.
Introduction: Cancer has become a public health problem worldwide, affecting individuals of different age groups, including children, young adults and older patients.
Objective: To determine the clinical profile, staging and standard of oncological treatment of the 10 most frequent primary sites of cancer in young patients (< 60 years) vs older patients (≥ 60 years old) diagnosed between 2000 and 2019 in Brazil.
Materials And Methods: This cross-sectional study used data from the secondary database of the Hospital Cancer Registry, available on the web www.
Oncol Ther
January 2025
Coordinator of the International Head and Neck Scientific Group, Padua, Italy.
Introduction: Laryngeal chondrosarcoma (CS) is a rare indolent malignant tumor. High-grade (G3), dedifferentiated (DD), and myxoid (MY) CSs are considered more aggressive subtypes due to their metastatic potential and relatively poor outcomes. The aim of this systematic review is to evaluate treatment modalities and survival outcomes in patients affected by these rarer CS subtypes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!